证券代码：301201 证券简称：诚达药业 公告编号：2025-037 诚达药业股份有限公司 第五届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 诚达药业股份有限公司（以下简称"公司"）第五届董事会第十四次会议于 2025 年 10 月 24 日在公司会议室以现场方式召开。会议通知已于 2025 年 10 月 21 日通过电话、邮件的方式送达全体董事。本次会议应出席董事 7 人，实际出 席董事 7 人，公司监事、高级管理人员列席会议。会议由董事长葛建利女士召集 和主持。本次会议的召集和召开符合有关法律、行政法规、部门规章和《公司章 程》的规定，形成的决议合法有效。 二、董事会会议审议情况 会议经全体董事讨论后形成如下决议： （一）审议通过《关于<2025 年第三季度报告>的议案》 经审议，董事会认为：公司《2025 年第三季度报告》的内容真实、准确、 完整地反映了公司 2025 年第三季度经营的实际情况，不存在任何虚假记载、误 导性陈述或者重大遗漏，报告编制和审核的程序符合法律、行政法规的要求。 具体内容详 ...

诚达药业股份有限公司 2025 年第三季度报告 诚达药业股份有限公司 2025 年第三季度报告 证券代码：301201 证券简称：诚达药业 公告编号：2025-039 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 □是 否 1 诚达药业股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 102,641,733.71 | 28.69% | 285 ...

Core Viewpoint - The medical services sector experienced a rise of 1.37% on October 24, with Bid Medicine leading the gains, while the Shanghai Composite Index closed at 3950.31, up 0.71% [1]. Group 1: Market Performance - The medical services sector saw significant individual stock movements, with Bid Medicine (688073) closing at 76.99, up 8.21% with a trading volume of 11,600 and a transaction value of 87.11 million [1]. - Other notable performers included Haoyuan Medicine (688131) at 85.07, up 6.30%, and Innovation Medical (002173) at 23.42, up 4.93% [1]. - The overall trading volume and transaction values for the sector indicated strong investor interest, with a total of 2.79 billion net inflow from major funds [2]. Group 2: Fund Flow Analysis - Major funds showed a net inflow of 2.79 billion, while retail investors experienced a net outflow of 826.12 million [2]. - Specific stocks like Innovation Medical (002173) had a net inflow of 2.20 billion from major funds, despite a net outflow of 1.43 billion from retail investors [3]. - Other stocks such as Kanglong Chemical (300759) and Meian Health (002044) also showed mixed fund flows, with significant net inflows from major funds but outflows from retail investors [3].

南方财经10月24日电，诚达药业(301201.SZ)公告，持股5%以上股东深圳前海晟泰投资企业（有限合 伙）于2025年10月22日通过集中竞价方式减持公司股份931,400股，占公司总股本比例0.60%。本次减持 后，前海晟泰持有股份由9,419,897股减少至8,488,497股，持股比例由6.09%下降至5.49%。 ...

诚达药业股份有限公司（以下简称"公司"）于 2025 年 9 月 5 日在巨潮资 讯网（www.cninfo.com.cn）披露了《关于持股 5%以上股东减持股份的预披露公 告》（公告编号：2025-033），股东深圳前海晟泰投资企业（有限合伙）（以下 简称"前海晟泰"）计划在减持计划公告披露之日起 15 个交易日后的 3 个月内 （2025 年 9 月 29 日至 2025 年 12 月 28 日）以集中竞价或大宗交易方式减持本 公司股份不超过 11,006,897 股（占本公司剔除回购专户股份数后总股本比例 7.27%）。 证券代码：301201 证券简称：诚达药业 公告编号：2025-036 诚达药业股份有限公司 关于持股 5%以上股东减持股份比例触及 1%整数倍的公告 持股 5%以上股东深圳前海晟泰投资企业（有限合伙）保证向本公司提供的信 息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 诚达药业股份有限公司董事会 2025 年 10 月 20 日至 2025 年 10 月 21 日，前海晟泰通过集中竞价方式累计 减持公司 ...

Automotive Industry - The core point of the report highlights the impressive performance of the Chinese automotive industry in the first three quarters of 2025, with strong growth in new energy vehicles (NEVs) [3][4] - In the first three quarters of 2025, production and sales of NEVs exceeded 11.24 million units, representing a year-on-year growth of 35.2% and 34.9% respectively, with a penetration rate of 46.1% [4] - In September 2025, NEV production and sales reached 1.617 million and 1.604 million units, showing a month-on-month increase of 16.3% and 15%, and a year-on-year increase of 23.7% and 24.6% [4] - The export volume of automobiles in the first three quarters of 2025 increased by 14.8% year-on-year, with a total export of 4.95 million vehicles [4] - The report suggests focusing on leading companies in the NEV supply chain and those with overseas market presence, as the increasing penetration rate of NEVs will drive the collaborative development of the entire industry chain [4][5] Investment Recommendations - The report indicates that the automotive sector is experiencing a resonance phase between new product cycles and technological advancements, particularly in smart driving and smart cockpit technologies, which are expected to drive continuous sales growth [5] - Continuous policy support for automotive consumption and the rising penetration rate of NEVs provide a broad market space for vehicle manufacturers [5] - In the components sector, the rapid increase in the penetration of smart components such as smart cockpits and electric drive systems is expected to benefit related companies [5] - The report maintains an "overweight" rating for the automotive industry, recommending attention to quality companies in the sector, such as Shuanghuan Transmission and Beite Technology [5] New Materials - The report notes a slight increase of 0.05% in the rare earth magnetic materials industry, outperforming the benchmark by 2.27 percentage points [7] - The prices of rare earth concentrates have accelerated their decline, with specific price drops reported for various rare earth minerals [9] - The report highlights the need to monitor the demand side closely, as the market's just-in-time transactions are primarily driven by basic needs, with expectations for demand to improve in the coming months [10] Medical Services - The report indicates a decline of 2.48% in the pharmaceutical and biological sector, with the medical services sub-sector experiencing a significant drop of 5.21% [11][12] - The current PE ratio for the medical services sector is 34.96, with a recent decrease of 1.96 from the previous week [13][14] - The report emphasizes the potential of ADC (Antibody-Drug Conjugates) and CDMO (Contract Development and Manufacturing Organization) in the innovative drug sector, projecting significant growth in the ADC outsourcing market [15][16] - The report maintains a "buy" rating for the medical services industry, recommending attention to high-growth companies and those with improving expectations, such as WuXi AppTec and Aier Eye Hospital [17] ETF Market Overview - As of October 17, 2025, there are 1,328 ETFs in the Shanghai and Shenzhen markets, with a total asset management scale of 55,264.48 billion [19] - The report notes that the average weekly change in shares for stock ETFs was an increase of 27.63 million shares, with significant increases in bank and brokerage ETFs [20] - The report recommends focusing on the automotive, coal, and agriculture sectors within the PB-ROE framework for ETF rotation strategies, highlighting the potential for these sectors to outperform [24]

| 1.基本情况 | | | --- | --- | | 信息披露义务人 | 深圳前海晟泰投资企业（有限合伙） | | 住所 | 深圳市前海深港合作区前湾一路 1 号 A 栋 201 室（入驻深圳市前海商 务秘书有限公司） | | 权益变动时间 | 2025 年 10 月 20 日至 2025 年 10 月 21 日 | | 权益变动过程 | 本次权益变动主要系前海晟泰因自身经营需要通过集中竞价交易减持 诚达药业股份 1,587,000 股，持有的公司股份占公司总股本的比例由 | | | 7.11%减少至 6.09%，权益变动触及 1%整数倍。 | | 股票简称 | 诚达药业 股票代码 301201 | 变动类型 增加□ 减少 一致行动人 有□ 无 是否为第一大股东或实际控制人 是□ 否 2.本次权益变动情况 股份种类（A 股、 B 股等） 减持股数（股） 减持股数占 总股本比例 （%） 减持股数占剔除回 购专户股份数后总 股本比例（%） A 股 1,587,000 1.03 1.05 合 计 1,587,000 1.03 1.05 本次权益变动方 式（可多选） 通过证券交易所的集中交易 协议转让 □ 通过证 ...

Market Overview - The medical services sector experienced a decline of 0.9% on October 22, with Sanbo Brain Science leading the drop [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Notable gainers in the medical services sector included: - Yaokang Biological (688046) with a closing price of 17.18, up 2.81% [1] - Aoyang Health (002172) with a closing price of 4.26, up 1.91% [1] - Haochen Medical (002622) with a closing price of 3.32, up 1.84% [1] - Significant decliners included: - Sanbo Brain Science (301293) with a closing price of 57.19, down 4.67% [2] - Chengda Pharmaceutical (301201) with a closing price of 33.98, down 4.50% [2] - XD Haoyuan Medical (688131) with a closing price of 79.90, down 2.07% [2] Capital Flow - The medical services sector saw a net outflow of 615 million yuan from institutional investors, while retail investors contributed a net inflow of 370 million yuan [2][3] - Key stocks with notable capital flows included: - Kanglong Chemical (300759) with a net inflow of 46.59 million yuan from institutional investors [3] - Aoyang Health (002172) with a net inflow of 10.44 million yuan from institutional investors [3] - Yaokang Biological (688046) with a net inflow of 9 million yuan from institutional investors [3]

Core Viewpoint - The medical services sector experienced a decline of 2.76% on October 17, with Sanbo Brain Science leading the drop. The Shanghai Composite Index closed at 3839.76, down 1.95%, while the Shenzhen Component Index closed at 12688.94, down 3.04% [1]. Summary by Category Market Performance - The medical services sector saw significant declines, with Sanbo Brain Science falling by 7.13% to a closing price of 58.96. Other notable declines included He Yuan Biological (-5.26%), Jiu Zhou Pharmaceutical (-4.70%), and Xin Li Cheng (-4.49%) [2]. - In contrast, Hai Te Biological and Cheng Da Pharmaceutical were among the few gainers, with increases of 6.23% and 3.15%, respectively [1][2]. Trading Volume and Value - The trading volume for Hai Te Biological reached 232,100 shares with a transaction value of 850 million yuan, while Cheng Da Pharmaceutical had a volume of 61,000 shares and a value of 200 million yuan [1]. - The overall medical services sector saw a net outflow of 1.181 billion yuan from major funds, while retail investors contributed a net inflow of 939 million yuan [2]. Fund Flow Analysis - Major funds showed a net inflow of 171 million yuan into Aier Eye Hospital, while other companies like Hai Te Biological and Cheng Da Pharmaceutical experienced mixed fund flows [3]. - Retail investors showed a significant net inflow into several stocks, indicating a potential shift in market sentiment despite the overall sector decline [3].

Group 1 - The insurance sector has thousands of billions of incremental funds waiting to enter the market, with a focus on long-term assessments for institutions [2] - A new regulatory framework requires public funds to increase their A-share market value by 10% annually over the next three years, addressing the volatility caused by retail investors [2] - As of the end of August, long-term funds held A-share market value of 21.4 trillion yuan, a 28% increase from the beginning of the year, with their turnover rate significantly lower than that of retail investors [2] Group 2 - OpenAI's release of the Sora 2.0 video generation model showcases advanced capabilities, including multi-angle storytelling and realistic visual effects [4] - Institutional investors are systematically increasing their holdings in AI computing power stocks, with notable net purchases in companies like Zhongke Shuguang and Inspur Information [4][6] - The advertising sector is also seeing growth, with the daily usage of AIGC creation platforms doubling within two weeks [6] Group 3 - The market shows a historical trend where the Wande All A Index has a 60% probability of rising in the first five trading days after the holiday [7] - The financial metrics indicate that the banking sector has a dividend yield of 6.84%, suggesting limited downside for the index due to high dividend assets [7] Group 4 - In October, 97 companies will have lock-up shares released, totaling a market value of 238.9 billion yuan, with Tianshan Shares alone accounting for 25.86 billion yuan [11] - There is an increasing trend in the willingness of industrial capital to reduce holdings, with the number of companies announcing reduction plans reaching a yearly high [11] Group 5 - The current market environment creates two types of investment opportunities: assets with a dividend yield over 5% and a PEG ratio below 1, and technology companies with R&D expenses exceeding 15% [13] - The domestic production rate of semiconductor equipment is increasing by 5 percentage points annually, indicating a positive trend in the sector [13] Group 6 - The average recovery period for retail investors entering the market on October 8, 2024, is projected to be nine months, highlighting the challenges faced by individual investors [15] - The impact of the AI technology revolution raises questions about the disparity between capital returns and labor returns, particularly in the context of content creation [15]